Prasterone for the treatment of systemic lupus erythematosus
Following on from information provided to NICE by the company in 2018, the appraisal of Masitinib for Prasterone for the treatment of systemic lupus erythematosus [ID392] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 392
Referral date 01 October 2000
Topic area
  • Musculoskeletal
  • Therapeutic procedures

Provisional Schedule

1st appraisal committee meeting: TBC
2nd appraisal committee meeting: TBC

Project Team

Assessment Group / Evidence Review Group: TBC
Communications manager: Fraser Woodward
Executive Lead: TBC
Project manager: TBC
Technical Lead: TBC

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
03 November 2022 Following on from information provided to NICE by the company in 2018, the appraisal of Masitinib for Prasterone for the treatment of systemic lupus erythematosus [ID392] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
03 November 2022 Discontinued. Following on from information provided to NICE by the company in 2018, the appraisal of Masitinib for Prasterone for the treatment of systemic lupus erythematosus [ID392] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.

For further information on our processes and methods, please see our CHTE processes and methods manual